STAT March 5, 2024
Helen Branswell

When Americans line up for flu vaccines next fall, they will almost certainly be getting vaccines that no longer contain protection against a family of flu viruses that appears to be extinct.

Experts who advise the Food and Drug Administration on vaccine-related issues voted unanimously on Tuesday to recommend that the FDA approve trivalent flu vaccines for the 2024-2025 season, instead of the quadrivalent, or four-in-one, shots that have been the industry standard for the past decade or so.

The Vaccines and Related Biological Products Advisory Committee — VRBPAC, as it’s known — has been pushing for the removal of one of the influenza B components in flu vaccines, the portion that targeted B/Yamagata viruses, for some time now. B/Yamagata...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: FDA, Govt Agencies, Healthcare System, Patient / Consumer, Provider, Public Health / COVID
Related Articles:
Insurer Denies Access To Drugs Granted Accelerated Approval By FDA
FDA Approves Third Tocilizumab Biosimilar
The Biden Administration’s Swan Song on Digital Health: Two FDA Guidances on Artificial Intelligence and FDA’s Defense of its Clinical Decision Support Guidance
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown

Share This Article